Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Academic Article

Abstract

  • Human immunodeficiency virus-infected women (n = 16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy. Copyright © 2007, American Society for Microbiology. All Rights Reserved.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Unadkat JD; Wara DW; Hughes MD; Mathias AA; Holland DT; Paul ME; Connor J; Huang S; Nguyen BY; Watts DH
  • Start Page

  • 783
  • End Page

  • 786
  • Volume

  • 51
  • Issue

  • 2